45.43
3.13 (7.40%)
| Previous Close | 42.30 |
| Open | 43.03 |
| Volume | 1,694,715 |
| Avg. Volume (3M) | 1,143,066 |
| Market Cap | 5,219,139,072 |
| Price / Sales | 13.14 |
| Price / Book | 20.89 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2026 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.63 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 31 Dec 2025 | 5,220,846 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (BMO Capital, 54.08%) | Buy |
| Median | 58.00 (27.67%) | |
| Low | 53.00 (Barclays, 16.66%) | Buy |
| Average | 58.86 (29.56%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 46.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 04 Mar 2026 | 70.00 (54.08%) | Buy | 47.43 |
| Barclays | 04 Mar 2026 | 53.00 (16.66%) | Buy | 47.43 |
| Citigroup | 04 Mar 2026 | 58.00 (27.67%) | Buy | 47.43 |
| 09 Jan 2026 | 55.00 (21.07%) | Buy | 42.18 | |
| Piper Sandler | 04 Mar 2026 | 58.00 (27.67%) | Buy | 47.43 |
| Truist Securities | 04 Mar 2026 | 55.00 (21.07%) | Buy | 47.43 |
| HC Wainwright & Co. | 03 Mar 2026 | 58.00 (27.67%) | Buy | 44.31 |
| 26 Jan 2026 | 58.00 (27.67%) | Buy | 44.89 | |
| UBS | 07 Jan 2026 | 60.00 (32.07%) | Buy | 44.23 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Jan 2026 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Scholar Rock Highlights 2026 Strategic Priorities |
| 05 Jan 2026 | Announcement | Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |